澳大利亚新南威尔士州上诉法院于周三驳回了Cosette Pharmaceuticals 终止对 Mayne Pharma 收购的请求，维持了先前的裁决，认定这家美国制药公司没有合法理由放弃交易。以下是部分细节：Cosette 于去年二月出价每股 7.40 澳元收购 Mayne，但随后试图退出，称 Mayne 财务表现恶化构成了重大不利变更，导致协议失效。
Australia's New South Wales Court of Appeal on Wednesday rejected Cosette Pharmaceuticals' bid to terminate its takeover of Mayne Pharma , upholding an earlier ruling that the US-based drugmaker had no valid grounds to abandon the deal. Here are some of the details: Cosette bid A$7.40 per share for Mayne in February last year but later tried to back out, saying a deterioration in Mayne's financial performance constituted a material adverse change that voided the agreement.
新南威尔士州上诉法院认定 Mayne 销售业绩的下降不足以达到《方案实施契约》所规定的重大不利变更门槛。
The NSW Court of Appeal found the decline in Mayne's sales performance was insufficient to meet the threshold for a material adverse change under the scheme implementation deed.
法院表示，评估收益影响时必须考虑该在澳交所上市公司所实现的成本节约。
The court said cost savings made by the ASX-listed firm had to be taken into account when assessing the earnings impact.
法院称：“Cosette 在两项理由上均未成立。审判法官认定 MPG 2025 财年第三季度的销售业绩的某些方面构成了不利变更，但未达到《方案实施契约》意义上的重大不利变更。”
"Cosette failed on both grounds. The trial judge found that aspects of MPG’s Q3 FY25 sales performance did constitute an adverse change, but did not qualify as a material adverse change within the meaning of the SID (scheme implementation deed)," the court said.
法院还驳回了 Cosette 关于 Mayne 对其 2025 年预期收益表现存在误导的主张。法院亦命令 Cosette 支付上诉的法律费用。
The court also rejected Cosette's claim that Mayne had misled it regarding its expected 2025 earnings performance. The court also ordered Cosette to pay the legal costs of the appeal.
此次价值 6.72 亿澳元（约合 4.697 亿美元）的收购遭到政治反对，南澳州州长彼得·马利纳斯卡斯批评该交易。联邦财政部长吉姆·查尔默斯于去年十一月以国家利益为由阻止了该交易。
The A$672 million ($469.7 million) takeover has faced political opposition, with South Australian Premier Peter Malinauskas criticising the transaction. Federal Treasurer Jim Chalmers blocked the deal in November last year on national interest grounds.
Mayne Pharma 于周三早些时候因等待裁决而暂停交易。
Mayne Pharma entered a trading halt earlier on Wednesday pending the decision.